DUBLIN - November 20, 2017 - Medtronic plc (MDT) today announced U.S. Food and Drug Administration (FDA) approval and U.S. commercial launch for its portfolio of Azure(TM) pacemakers with ...
Medtronic plcMDT announced the receipt of FDA approval and commercial launch of its portfolio of Azure pacemakers with BlueSync technology. According to the company, this technology enables secure, ...
Pacemaker therapy that boosts impaired heart rate (HR) response to exertion failed to improve exercise capacity or quality of life in patients with heart failure with preserved ejection fraction ...
Azure pacemakers feature Medtronic-exclusive BlueSync technology, which enables automatic, secure wireless remote monitoring via the Medtronic CareLink(TM)Network, providing timely alerts of ...
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here. Medtronic plc (NYSE: MDT) today announced U.S. Food and Drug Administration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results